Effectiveness and safety of molnupiravir among patients with mild to moderate COVID-19: a prospective, observational, cohort study

This study evaluates the effect of molnupiravir on clinical improvement, viral clearance and antibody responses of COVID-19 patients who previously developed immunity through vaccination or prior infection. This multi-center, prospective, observational study included all mild adult COVID-19 cases for whom molnupiravir was recommended during the study period. The primary outcome was hospitalization, death or new oxygen need due to COVID-19 within 28 days of follow-up. The effects of molnupiravir on viral clearance, serum biochemical tests and SARS-CoV-2 antibody levels were also assessed. A total of 844 patients (402 molnupiravir, 442 no molnupiravir) were included. The mean age was 66, 75% of them were vaccinated. The primary outcome occurred in 8 patients, with no significant difference different between propensity score-matched groups. Molnupiravir showed no effect on clinical improvement. Viral clearance was higher in the molnupiravir group on day 3, but higher in the untreated group by day 10. Serum SARS-CoV-2 antibody levels on day 28 were lower in the molnupiravir group. The effectiveness of molnupiravir in reducing hospitalization and death may be insufficient in previously immune COVID-19 patients. Additionally, molnupiravir may reduce day-28 serum SARS-CoV-2 antibody level.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-04-16
DOI
https://doi.org/10.1038/s41598-026-44971-x
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness and safety of molnupiravir among patients with mild to moderate COVID-19: a prospective, observational, cohort study

Mahir Kapmaz, Sevim Meşe, Seniha Başaran, Mehtap Aydın et al.
Scientific Reports
SARS-CoV-2 and COVID-19 Research
article

Effectiveness and safety of molnupiravir among patients with mild to moderate COVID-19: a prospective, observational, cohort study

Mahir Kapmaz, Sevim Meşe, Seniha Başaran, Mehtap Aydın, Meryem Çalışkan, hüsna çevik, Belgin Coşkun, Önder Ergönül, Serap Şimşek Yavuz, Neslihan UYAR, Mert Ahmet Kuşkucu, Aysun Benli, Füsun Can, Özlem Aydın, Sezen Fansa, Özlem Altuntaş-Aydın, Rahmet Guner, Ali Ağaçfidan, Hasan Yağmur, Mustafa Önel, Nilsun Altunal, Duygu Korkut Akyürek, Elif Mukime Sarıcaoğlu, Yeşim Tok, Sezen Özge Özen, Alpay Azap, Gülsüm Öztürk-Emiral, Elif Selcen Beng, Müge Ayhan, İlker İnanç-Balkan, Fatma Zehra Güneşer, Mihriban Aksoy, Alper Gündüz, Filiz Pehlivanoğlu, Burcu Atasoy Bozan, Melek-Nur Aslan
article en

Abstract

This study evaluates the effect of molnupiravir on clinical improvement, viral clearance and antibody responses of COVID-19 patients who previously developed immunity through vaccination or prior infection. This multi-center, prospective, observational study included all mild adult COVID-19 cases for whom molnupiravir was recommended during the study period. The primary outcome was hospitalization, death or new oxygen need due to COVID-19 within 28 days of follow-up. The effects of molnupiravir on viral clearance, serum biochemical tests and SARS-CoV-2 antibody levels were also assessed. A total of 844 patients (402 molnupiravir, 442 no molnupiravir) were included. The mean age was 66, 75% of them were vaccinated. The primary outcome occurred in 8 patients, with no significant difference different between propensity score-matched groups. Molnupiravir showed no effect on clinical improvement. Viral clearance was higher in the molnupiravir group on day 3, but higher in the untreated group by day 10. Serum SARS-CoV-2 antibody levels on day 28 were lower in the molnupiravir group. The effectiveness of molnupiravir in reducing hospitalization and death may be insufficient in previously immune COVID-19 patients. Additionally, molnupiravir may reduce day-28 serum SARS-CoV-2 antibody level.

Scientific Reports
Üsküdar University (TR), Ministry of Health (TR), Koç University (TR), Ankara University (TR), Bilkent University (TR), University of Health Science (KH), Izmir Kâtip Çelebi University (TR), Fatih University (TR), Ministry of Health (BN), Ministry of Health (UA), Ümraniye Eğitim ve Araştırma Hastanesi (TR), Istanbul University-Cerrahpaşa (TR), Education Training And Research (US), İstanbul Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi (TR), Ankara Bilkent City Hospital (TR), Istanbul University (TR)
Zero hunger
Openalex Percentile: Top 16%
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.